Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
217.97
+8.22 (+3.92%)
Streaming Delayed Price
Updated: 11:11 AM EDT, Jul 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
60
61
Next >
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
↗
January 03, 2025
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
Via
Benzinga
17 Analysts Assess Biogen: What You Need To Know
↗
January 02, 2025
Via
Benzinga
10 Worst Performing Large-Caps Last 12 Months
↗
December 26, 2024
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.
Via
Talk Markets
Topics
Stocks / Equities
Large-Cap Stocks In Trouble - Saturday, Dec. 21
↗
December 21, 2024
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns.
Via
Talk Markets
Topics
Stocks / Equities
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
↗
December 20, 2024
Via
Benzinga
Assessing Biogen: Insights From 19 Financial Analysts
↗
December 09, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Biogen Through Analyst Insights
↗
November 14, 2024
Via
Benzinga
Evaluating Biogen: Insights From 17 Financial Analysts
↗
November 04, 2024
Via
Benzinga
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory?
↗
December 11, 2024
Super Micro faces potential delisting from Nasdaq 100 Index due to underperformance and auditing scandal. Uncertainty surrounds its future.
Via
Benzinga
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
↗
December 09, 2024
Jefferies downgrades Biogen with a reduced price target, citing pipeline setbacks, slow Leqembi sales, and challenges from declining Ocrevus royalties.
Via
Benzinga
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
↗
December 09, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
December 02, 2024
Via
Benzinga
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
↗
November 26, 2024
Via
The Motley Fool
Biogen Analysts Slash Their Forecasts After Q3 Results
↗
October 31, 2024
Via
Benzinga
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum
↗
October 30, 2024
The biotech giant also raised full-year EPS guidance.
Via
Investor's Business Daily
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
↗
November 20, 2024
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.
Via
Benzinga
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
November 19, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
↗
November 18, 2024
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges.
Via
Benzinga
This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
↗
November 18, 2024
Via
Benzinga
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
↗
November 15, 2024
Via
Benzinga
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
November 14, 2024
From
Biogen Inc.
Via
GlobeNewswire
This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
↗
October 31, 2024
Via
Benzinga
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
October 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
↗
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
↗
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
Biogen (BIIB) Q3 2024 Earnings Call Transcript
↗
October 30, 2024
BIIB earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook
↗
October 30, 2024
Biogen's Q2 revenue fell 3% to $2.47 billion exceeding estimates, with adjusted EPS of $4.08. Multiple sclerosis sales dipped, while new products buoyed performance.
Via
Benzinga
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 29, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
October 29, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
October 29, 2024
From
Biogen Inc.
Via
GlobeNewswire
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
60
61
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
